Your address will show here +12 34 56 78
Invest in Innovation
AVEX.AI Tracker Certificate
Offers investors exposure to the AVEX token.
  • Text Hover
A New Instrument for Investors
Gain Exposure to Blockchain-Derived Health Markets through a Familiar Product
AVEX.AI is the first-ever tracker certificate issued on the Swiss Stock Exchange (The Six) designed to participate in the dynamic tokenized health market. It is a structured product following Swiss guidelines that utilizes a securitization pathway via wrapped tokens.

AVEX.AI offers a secure way of participating in blockchain-derived assets, ensuring that investors can take advantage of the opportunities in this new exponential space, while being secure with the type of instrument used.

With AVEX.AI, there is no learning curve or technological specialization required to access new health cryptoassets. It provides a simple tool that works with the familiarity of classic investment.

 



 

AVEX.AI Product Profile
The AVEX Token is the blockchain-derived currency that allows consumers and other members of the BIOSPHERES Network to transact within the BIOSPHERES platform. It was designed to capture the value of the health innovation sector. BIOSPHERES is a marketplace that accommodates billions of dollars in biotech/medical product offerings that offer solutions, from Alzheimer’s, to ALS, and Cancer, to millions of patients worldwide.

The AVEX Token is also the first to launch a new digital asset on a stock exchange through a structured product. Opportunities for new token offerings were previously exclusive to a highly technical community that generated unprecedented returns for many early investors. With this new alternative investment product, we make it as easy as buying a stock and reduce the risks that have been associated with other cryptocurrency offerings.
Name
AVEX.AI Tracker Certificate on Aevolve Token (AVEX)
ISIN Number
Upon Request
Classification
Tracker-Certificate (Code 1300) of the Swiss Derivative Map, as amended from time to time by the Swiss Structured Products Association (www.svsp-verband.ch)
Underlying Asset
AVEX token is the sole and exclusive cryptoasset that is used to purchase unique health tech products in BIOSPHERES, a tokenized marketplace for health innovation offerings.
Total Amount
USD 100’000’000.00 (Maximal Amount)
Issue Size
100’000 Certificates
Minimum Trade Size
10 Certificates and 1 Certificate thereafter
Subscription Period
To Be Announced
Issuing Company
FP ISSUER LIMITED (GUERNSEY)
Merging Traditional Finance with Innovation
Aevolve understands the value of working with existing regulatory framework to provide timely access and mutual benefits through an unprecedented interaction of investors and innovators.
Through tokenization and securitization of digital assets, value is captured in the health innovation space by introducing cutting-edge products and making them accessible to the public. By integrating this new cryptoasset strategy with trusted investment protocols, a new hybrid market is invented that brings the trillion-dollar derivative market into innovation financing, and enables investment opportunities and liquidity to flow between both ecosystems.
Safe
AVEX.AI is a classic investment that is understandable and avoids technological mishaps in large-scale investing, such as mismanagement of private keys. It has eliminated such risks by securely vaulting the underlying AVEX digital asset, and allows for free trading on traditional exchanges without exposure to new user related security risks.
Simple
AVEX.AI is a familiar product that requires no learning curve or technological shift. Investors that prefer traditional investment methods will find it the ideal, user-friendly option for accessing cutting-edge crypto markets.
Sustainable
There is a tremendous global need in the health sector, with many diseases constantly requiring solutions. This presents a wide range of opportunities to provide products or services that address these countless medical needs for the world’s growing population, new demand is continuously created. Therefore, market relevance is sustained fueling growth and new opportunities.
Structured Product
This is a first-in-the-world financial product that gives traditional financial managers exposure to a cryptotoken at it earliest stage. The regulatory and compliance landscape for cryptoassets is unclear and uncertain. This structured asset helps to break through fear, uncertainty and doubt associated with a new technology.
Social Impact
This investment tool is geared towards sustainability and future success by being a well-rounded mechanism beyond marketing and financial performance. It was designed with social impact ingrained in the business model, as well as well-designed governance levers in mind to protect asset owners. Further value is added by benefiting large communities in terms of an active donation market. By today’s standards ESG (Environmental, Social and Governance) Investing is considered a sound metric for investment strength. It proves to be a more sustainable method of investment, relying on transformative social contributions that outlast short-term marketing and price-boosting efforts.
Solid
Pricing models and projections are based on actual solutions that will launch as part of BIOSPHERES offerings. This is a high-practicality model for executing utility based on existing technologies. It is a measurable, executable and relatively low-cost build with realistic and achievable targets. With Year One targets secured, the project continues to ensure a lineup of multi-billion dollar offerings.
  • Text Hover
  • Text Hover
  • Text Hover
  • Text Hover
  • Text Hover
SUBSCRIBE










Select country

Select language


Important Information

The information on this website is intended only for persons residing or having their registered office in Switzerland.

By using this website, you expressly confirm that you are a resident of the selected country. Aevolve AG explicitly declines any responsibility for the distribution of information or documents to natural or legal persons who provide incorrect information regarding their legal place of residence or registered office.

The financial products mentioned on this website are derivative financial instruments. They do not qualify as units of a collective investment scheme in the meaning of Article 7 et seqq. of the Swiss Federal Act on Collective Investment Schemes (CISA) and are therefore neither supervised by the Swiss Financial Market Supervisory Authority (FINMA) nor registered with FINMA. Investors do not benefit from the specific investor protection provided under the CISA.

Terms of use and legal information 

 

By using the Aevolve AG website (hereinafter “Website”), you confirm that you have understood and accept the legal information, important notes and terms of use presented here. If you do not accept the terms of use, please refrain from using this Website.

Proprietary information

 

All intellectual property rights (e.g. copyright, design and trademark rights) to the material presented on the Website belong to Aevolve AG or its platform partners, who will enforce these rights to the full extent of applicable laws. Any form of reproduction, republication or distribution of the content of this Website requires the written consent of Aevolve AG in Zurich (Switzerland) and the respective indication of the source.

No part of this Website is designed to grant any form of license or user rights to images, text, trademarks or logos. No act of downloading or copying content from the Website will transfer or bestow any legal entitlement to the Website’s software or materials.

Conflicts of interest

 

From time to time, the issuers and/or lead manager and/or their third-party agents may, for their own account or for the account of others, take positions in securities, currencies, financial instruments or other assets that serve as an underlying asset to the products on this Website. They may buy or sell these assets, act as market makers, and simultaneously operate as seller or as purchaser. The trading or hedging activities of the issuers and/or lead manager and/or their third-party agents may influence the price of an underlying asset and may influence whether or not the relevant barrier level is reached (if such a level exists).

Performance

 

Past performance is not an indication or guarantee of future performance of a product or underlying asset. The value of any investment may be subject to fluctuations and, in some circumstances, investors may not recover the original amount invested. Exchange rate fluctuations may also cause the value of an investment to rise or fall.

Selling restrictions

 

No action has been or will be taken to permit a public offering of the products or possession or distribution of any offering material in relation to the products in any jurisdiction, where such action for that purpose is required. Selling Restrictions Consequently, any offer, sale or delivery of the products, or distribution or publication of any offering material relating to the products, may only be made in or from any jurisdiction in compliance with applicable laws and regulations not imposing any obligations on the issuers or the lead manager. Possible limitations resulting from legal restrictions with regard to cross-border communication and cross-border business concerning the products and related information remain reserved. The most important jurisdictions where the products may not be publicly distributed are EEA, UK, Hong Kong and Singapore.

The products may not be offered or sold within the USA, or to or for the account or benefit of US persons (as defined in Regulation S).

Detailed information on selling restrictions is published in the respective issuance programme, which is published on this Website and at aevolve.health.

We are hiring

Are you looking for job?

We are a fairly small, flexible design studio that designs for print and web. We work flexibly with Send us your resume & portfolio